Bondronat® Injection (Ibandronic Acid)
Compared with: Blackmores Conceive Well Gold 28 Tablets + 28 Capsules

Bondronat Injection (Ibandronic Acid 6 mg/3 mL) is a nitrogen‑containing bisphosphonate administered intravenously every 3–4 weeks to prevent skeletal‑related events in metastatic bone disease and to treat tumour‑induced hypercalcaemia. It inhibits osteoclast‑mediated bone resorption, increasing bone density and reducing fracture risk
Ibandronic Acid (as sodium salt) – 6 mg per 3 mL vial
Ibandronate

Bonviva® (oral formulation)

Boniva® Injection (US)

Bondronat® (EU)

Iasibon® (in some countries)

Targets bone mineral, binding preferentially at sites of active resorption.

Inhibits farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, disrupting prenylation of small GTPases (e.g., Ras, Rho), essential for osteoclast function and survival.

Induces osteoclast apoptosis, reducing bone resorption and turnover
Prevention of Skeletal‑Related Events in patients with breast cancer and bone metastases (pathological fractures, spinal cord compression, need for radiotherapy or surgery)
Treatment of Tumour‑Induced Hypercalcaemia with or without bone metastases

Postmenopausal Osteoporosis in women at high fracture risk (off‑label for injection, but primarily oral)
Indication Dose Schedule Administration
Skeletal‑Event Prevention (bone mets) 6 mg IV Every 3–4 weeks Infuse over ≥15 minutes in  ≥50 mL saline
Medicines.org.uk
Tumour‑Induced Hypercalcaemia 4 mg IV Single dose; may repeat after 7 days as needed
MedlinePlus
Infuse over 2 hours; ensure adequate hydration
Postmenopausal Osteoporosis (off‑label) 3 mg IV Every 3 months (alternative regimen) Infuse over 15–30 minutes

Preparation: Reconstitute vial with sterile water for injection; then dilute in sodium chloride 0.9 % for infusion.

Monitoring: Ensure adequate serum calcium and renal function prior to administration.
Formulation: Concentrate for solution for infusion (6 mg/3 mL)

Route: Intravenous infusion

Legal Status: Prescription Only Medicine
Pregnancy & Breastfeeding: No clinical data; avoid unless benefit outweighs risk.

Renal Impairment: Contraindicated in patients with creatinine clearance <30 mL/min or acute renal impairment.

Hypocalcaemia: Correct existing hypocalcaemia before treatment.

Hydration: Ensure adequate hydration pre‑ and post‑infusion to reduce renal toxicity.Flu‑like symptoms (fever, myalgia)

Arthralgia, back pain

Nausea, vomiting

Transient hypocalcaemia
Osteonecrosis of the jaw (ONJ)

Atypical femoral fractures

Renal failure

Severe acute phase reactions (fever, hypotension)
Osteonecrosis of the Jaw: Perform dental assessment prior to therapy; maintain oral hygiene.

Atypical Fractures: Monitor for thigh or groin pain; evaluate with imaging.

Acute Phase Reactions: Pre‑medicate with acetaminophen if necessary.

Electrolyte Monitoring: Check calcium, phosphate, and magnesium levels; supplement vitamin D and calcium as indicated.
Therapeutic Class: Antiresorptive Agent

Pharmacologic Class: Nitrogen‑Containing Bisphosphonate

Legal Category: Prescription Only
Aminoglycosides / Loop Diuretics: Additive nephrotoxicity—avoid concurrent use.

Calcium‑Containing Products: Impair ibandronate absorption—separate administration by ≥2 hours if oral.

NSAIDs: May increase risk of gastrointestinal adverse events.

Other Bisphosphonates: Do not co‑administer.
Morris et al. (2001): Ibandronate 6 mg IV every 3 months reduced vertebral fracture risk by 50 % versus placebo in postmenopausal osteoporosis
Rosen et al. (2007): Monthly ibandronate showed non‑inferior increases in bone mineral density compared to daily dosing.

Serpa Neto et al. (2019): Meta‑analysis confirmed bisphosphonates reduce skeletal‑related events in metastatic cancer by >25 %.

FAQs – Bondronat® Injection (Ibandronic Acid)
Q1. How long does the infusion take?
A: At least 15 minutes for skeletal‑event prevention dose; 2 hours for hypercalcaemia regimen.

Q2. Can patients with kidney issues receive Bondronat?
A: No—contraindicated if creatinine clearance <30 mL/min.

Q3. How soon will I see improvements in bone pain?
A: Pain relief may occur within days, but full benefit in skeletal‑event reduction is seen over several months.

Q4. Is calcium supplementation required?
A: Yes—ensure adequate calcium and vitamin D intake to prevent hypocalcaemia.

Q5. What precautions for dental health?
A: Dental exam before therapy and avoid invasive dental procedures during treatment.

Q6. Can Bondronat treat osteoporosis off‑label?
A: Yes—IV ibandronate is used every 3 months for osteoporosis when oral therapy is unsuitable.

Q7. What if I miss an infusion?
A: Schedule as soon as possible; maintain the 3–4 week interval for metastatic indications.
Bondronat Injection, Ibandronic Acid IV, Bisphosphonate Injection, Metastatic Bone Disease Therapy, Hypercalcaemia Treatment, EZ Chemist, Skeletal‑Event Prevention, Oncology Bone Protection, IV Ibandronate Guide